Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

What Is the Role of Immunotherapy in Allergic Diseases?

Summary

Immunotherapy is a controversial treatment for allergic diseases. However, controlled studies, either with a control group or as placebo-controlled double-blind trials, have documented a significant efficacy in Hymenoptera allergy, rhinitis and asthma. No strict scientific guidelines as to the use of immunotherapy can be provided. However, the 1993 Immunotherapy Position Paper of the European Academy of Allergology and Clinical Immunology recommended immunotherapy for patients with an unequivocal IgE-mediated disease who do not respond adequately to allergen avoidance and who require prophylactic topical corticosteroids for long periods. The clinical benefit, risk and potential preventive aspects of immunotherapy should be carefully assessed. Immunotherapy should as a routine only be initiated with allergens that have been shown in controlled studies to have clinical efficacy and safety. A treatment approach using immunotherapy as a supplement to pharmacotherapy is recommended, thereby interfering broadly with the pathophysiological mechanisms of allergic inflammation.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Grant IWB. Does immunotherapy have a role in the treatment of asthma? Clin Allergy 1986; 16: 7–16

  2. 2.

    Malling H-J, Weeke B. EAACI Immunotherapy Position Paper. Allergy 1993; 48 Suppl. 14: 9–35

  3. 3.

    National Institutes of Health. International Consensus Report on Diagnosis and Management of Asthma. Publication no. 92-3091, 1992

  4. 4.

    British Society of Allergy and Clinical Immunology. Position Paper on Immunotherapy. Clin Exp Allergy 1993; 23: 1–44

  5. 5.

    Kay AB. Asthma and inflammation. J Allergy Clin Immunol 1991; 87: 893–910

  6. 6.

    Ricci M, Rossi O, Bertoni M, et al. The importance of Th2-like cells in the pathogenesis of airway allergic inflammation. Clin Exp Allergy 1993, 23: 360–9

  7. 7.

    Bousquet J. Microscopic anatomy of bronchial asthma and its implications regarding pathogenesis. Insights Allergy 1990; 4: 1–5

  8. 8.

    Creticos PS. Immunotherapy in asthma. J Allergy Clin Immunol 1989; 83: 554–62

  9. 9.

    Van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus). Eur Respir J 1992; 5: 318–22

  10. 10.

    Durham SR, Varney V, Gaga M, et al. Immunotherapy and allergic inflammation. Clin Exp Allergy 1991; 21: 206–10

  11. 11.

    Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92: 644–51

  12. 12.

    Malling H-J, Stahl Skov P. Diagnosis and immunotherapy of mould allergy. VIII. Qualitative and quantitative estimation of IgE in Cladosporium immunotherapy. Allergy 1988; 43: 228–38

  13. 13.

    Rak S, Björnson A, Håkanson L, et al. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lungs of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol 1991; 88: 878–88

  14. 14.

    Müller U, Mosbech H. EAACI Immunotherapy with Hymenoptera venom position paper. Allergy 1993; 48: 37–46

  15. 15.

    Bousquet J, Hejjaoui A, Michel F-B. Specific immunotherapy in asthma. J Allergy Clin Immunol 1990; 86: 292–305

  16. 16.

    Norman PS. Immunotherapy. In: Melillo G, Norman PS, Marone G, editors. Respiratory allergy. Toronto: B.C. Decker Inc., 1990: 3–15

  17. 17.

    Bousquet J, Michel F-B. Advantages in specific immunotherapy. Clin Exp Allergy 1992; 22: 889–96

  18. 18.

    Creticos PS. Immunotherapy with allergens. JAMA 1992; 268: 2834–9

  19. 19.

    Malling H-J. Clinical efficacy of allergen immunotherapy. ISI Atlas Sci 1988; 1: 215–9

  20. 20.

    Malling H-J. Immunotherapy in mold allergy. Clin Rev Allergy 1992; 10: 237–51

  21. 21.

    Corrigan C. Mechanisms of glucocorticoid action in asthma: too little, too late. Clin Exp Allergy 1992; 22: 315–7

  22. 22.

    Lundgren R, Soderberg M, Horstedt P, et al. Morphological studies on bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur Respir J 1988; 1: 883–9

  23. 23.

    Thompson RA. The current status of allergen immunotherapy (hyposensitisation): report of WHO/IUIS working group. Allergy 1989; 44: 369–79

  24. 24.

    Tabar AI, Garcia BE, Rodriguez A, et al. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993; 48: 450–3

  25. 25.

    Reid MJ, Lockey RF, Turkeltaub PC, et al. Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 1993; 92: 6–15

  26. 26.

    Stewart II GE, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992; 90: 567–78

Download references

Author information

Correspondence to Dr Hans-Jørgen Malling.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Malling, H. What Is the Role of Immunotherapy in Allergic Diseases?. Clin. Immunother. 2, 240–247 (1994). https://doi.org/10.1007/BF03258525

Download citation

Keywords

  • Asthma
  • Adis International Limited
  • Rhinitis
  • Allergic Disease
  • Allergy Clin Immunol